12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Other News

Optimer Pharmaceuticals Inc. Inc. cancer news

Optimer plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology is conducting a Phase II/III trial of OPT-822/821 to treat metastatic breast cancer. The subsidiary has rights from Optimer to the product, which is a combination of an adjuvant with carbohydrate antigen globo-H linked to a protein carrier. Optimer expects to...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >